[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:mantle-cell-lymphoma:cd22-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Mantle Cell Lymphoma","CD22 Gene",3,[8,16,22],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[12],"Phase 1","RECRUITING","2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06340737","AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w\u002FRecurrent\u002FRefractory B Cell Lymphomas",[12],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.925479Z",{"nct_id":23,"title":24,"phases":25,"status":26,"updated_at":27,"content_modified":28},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z"]